The impact of comorbidities on the efficacy of IL-6 inhibitor olokizumab compared to adalimumab in a randomized controlled trial
Authors' conclusion
This post hoc analysis of the phase III CREDO-2 study suggests that the presence of at least one CCI comorbidity, including common disorders such as chronic pulmonary diseases and cardiovascular diseases, does not affect the OKZ treatment results in RA patients.
Study context
- Population
- Patients with active rheumatoid arthritis (RA) in the CREDO-2 trial treated with olokizumab (OKZ) (q4w or q2w), ADA or placebo
- Participants
- 1,402 patients
- Comparison
- Patients with comorbid conditions (modified Charlson Comorbidity Index (mCCI) ≥ 2) vs without (mCCI = 1), within OKZ, ADA and placebo treatment
- Primary endpoint
- Proportions of patients with CDAI ≤ 10 and CDAI ≤ 2.8
- Follow-up
- Week 24
Methodological detailsphase III
- Phase III
Primary result
As reported in the abstract
3 and 6 months
- No significant difference in efficacy between OKZ q4w or q2w-treated NCC and CC groups at 3 and 6 months
- Same observed for placebo
- Comorbidities reduced CDAI ≤ 10 and ACR50 outcomes upon ADA treatment at 6 months
- Post hoc analysis
Further findings
Proportion with mCCI ≥ 2 · baseline
- Similar in all groups
- ≈25%
Original publication
The impact of comorbidities on the efficacy of IL-6 inhibitor olokizumab compared to adalimumab in a randomized controlled trial. Arthritis Res Ther. Published 14 November 2025. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →